Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 12/20 | 0.43 |
| ▸ | LCK | P06239 | 5/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19933282 | 0.89 | ENPP1 (0.53) | PDE10AENPP1EGFRLCKKDR | |
| SCHEMBL20813470 | 0.84 | EGFR (0.52) | EGFRLCKKDRGAKRET | |
| SCHEMBL20050180 | 0.84 | KDR (0.43) | ENPP1EGFRLCKKDRGAK | |
| SCHEMBL23501083 | 0.83 | ENPP1 (0.63) | ENPP1EGFRLCKKDRSRC | |
| SCHEMBL23500791 | 0.83 | RET (0.43) | PDE10AENPP1EGFRLCKKDR | |
| SCHEMBL20813476 | 0.81 | EGFR (0.52) | EGFRLCKKDRGAKRET | |
| SCHEMBL21614043 | 0.76 | RET (0.43) | PDE10AENPP1EGFRLCKKDR | |
| SCHEMBL856568 | 0.76 | ENPP1 (0.63) | ENPP1EGFRLCKKDRSRC | |
| SCHEMBL30264799 | 0.76 | ENPP1 (0.63) | ENPP1EGFRLCKKDRSRC | |
| SCHEMBL3301604 | 0.75 | KDM1A (0.58) | EGFRKDRGAKFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210276972-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2021-09-09 | — | — | US | disclosed |
| US-10457664-B2 | Quinazoline derivatives as VEGF inhibitors | GENZYME CORPORATION (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190002433-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT4, FLT1, KDR | PDE10A 2058/4885ENPP1 3518/4885EGFR 199/4885 |
| US-20210276972-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | PDE10A 2482/4885ENPP1 3087/4885EGFR 207/4885 |
| US-10457664-B2 | Quinazoline derivatives as VEGF inhibitors | FLT1, FLT4, KDR | PDE10A 2162/4885ENPP1 3683/4885EGFR 179/4885 |
| US-20190002433-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | PDE10A 2162/4885ENPP1 3683/4885EGFR 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.